Business ❯Pharmaceutical Industry ❯Drug Development ❯Psychedelic Drugs

FDA Approval Process

FDA Declines MDMA for PTSD Treatment, Requests Further Trials

The decision marks the first time the agency has considered a Schedule I psychedelic for medical use, highlighting ethical and safety concerns.

FDA Rejects MDMA for PTSD Treatment, Requests More Trials